Currently Viewing:
Currently Reading
Suspension of a Rural Syringe Service Program Increased Risks of HIV and HCV Acquisition
May 23, 2019 – Wallace Stephens
LifeScan Finds Partner to Move Into CGM Market
May 23, 2019 – Mary Caffrey
Lenalidomide Beats Standard of Care in Smoldering MM
May 23, 2019 – Samantha DiGrande
What We're Reading: Addressing Maternal Care Disparities; Eggs and Stroke Risk; CBD for Opioid Addiction
May 23, 2019 – AJMC Staff
High-Deductible Insurance Plans Create Barriers to COPD Care
May 22, 2019 – Wallace Stephens
Patients With Ovarian Cancer Could Benefit From More Genetic Testing
May 22, 2019 – Laura Joszt
What We're Reading: Vermont AG Sues Sackler Family; Half-Price Insulin; Asthma Rates Fall in LA
May 22, 2019 – AJMC Staff
Increasing Use of Primary Care May Lower Rates of Respiratory Failure
May 22, 2019 – Wallace Stephens
African American COPD Patients Underutilize Pulmonary Rehabilitation
May 21, 2019 – Wallace Stephens

Antibody May Suppress HIV for Up to 4 Months in Patients Halting ART Regimens

Jaime Rosenberg
In a study of 29 virally suppressed patients who discontinued antiretroviral therapy (ART), every patient was able to maintain viral suppression from infusions of an antibody that blocks the HIV-binding site on CD4+ T cells.
Results of a phase 2 study are indicating that infusions of an antibody that blocks the HIV-binding site on CD4+ T cells may be able to suppress HIV for up to 4 months in patients undergoing a short-term pause in their antiretroviral therapy (ART).

Among the 29 virally suppressed patients in the study, every patient treated with UB-421 maintained viral suppression. There were intermittent viral blips in 8 (28%) patients, ranging from 21 to 142 copies per millimeter, but no patient had plasma viral rebound to more than 400 copies per milliliter.

“This is another modest advance in the tools that we now have in our armamentarium to treat people with HIV,” said Anthony S. Fauci, MD, director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases, in an interview with The American Journal of Managed Care®.

Unlike previous approaches using broadly neutralizing antibodies (bNAbs) against HIV, UB-421 is directed at the receptor of the virus on the cell, Fauci explained. Typically, infusions of bNAbs have suppressed HIV for 2 weeks by targeting the HIV virus itself, but the method has led to the development of antibody-resistant virus in the absence of ART.

According to Fauci, these findings have implications for 3 types of patients, including those who experience ART resistance and those who experience ART-related toxicity. It also has implications for patients with pill fatigue who, despite doing well on their ART regimen, experience psychological push back from the daily reminder of infection.

“There is a subset of people who would prefer to come in at certain intervals and get an infusion of an antibody that can effectively suppress the virus and get them off the requirement of a single pill or a few pills a day of antiretroviral drugs, and that’s exactly what this particular antibody does,” he said.

Upon enrollment in the study, patients discontinued their normal regimens of ART at the time of infusion or 1 week later, depending on their regimen. While 14 of the patients received 8 regular weekly infusions of UB-421 (10 mg per kg of body weight), 15 received 8 higher-dose infusions every other week (25 mg per kilogram of body weight). Following the end of the 8- or 16-week periods, all patients resumed treatment with their ART regimens.

Rash, mostly grade 1, was a common and transient adverse event, with 1 patient discontinuing infusions as a result.

Looking forward, Fauci said that an extension of this study is needed due to the small sample size. Researchers will also likely modify the antibody so that patients can receive infusions at longer intervals, such as every 3 or 4 months, he said.


Wang C, Wong W, Tsai H, et al. Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption [published online April 18, 2019]. N Engl J Med. doi: 10.1056/NEJMoa1802264.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up